"Expects to grow at about 25% growth in next couple of years"
Here are the key takeaways 🧵👇
Business Updates:
• Sales and PAT grewt by 89% and 50.8% YoY
• Green field plant expansion in Karnataka
• Brown field CTP line to be set up in UAE and a BOPET line in Poland
• Started trial runs in Poland plans.
• Mgmt expects largest volume gwth with completion of expansion
• Margin and Packing business were but lower in QoQ basis, because of reversal of decline in raw material prices which was there in Q1 and Q2.
• Hence the margins on these front were lower compare to Q1 and Q2.
• Focus remains now on value added products.
Target:
• Expected 25% gwth in revenue with respect to volume and value added product in next couple of years
Margins:
• Mgmt dont expects lag with respect to competitive levels. Polyplex, SRF is in films business. While Uflex, has many value streams which makes margins better
Return Matrix- Investment
• Uflex looks for 20%. IRR But there could be situation where margins got squeeze for certain period of time.
• After 2011, there was lull period with limited margins exposure and then again growth puck up in 2017 and everyone expands during this time.
• In India, most of the players works on 10-11% margins which is not sustainable.
ROE Still in single digit:
• Looking at the expansion point of view one cannot expect higher ROE, while on Uflex point of view mgmt would wait for 1-2 year for higher growth ratios.
Capital Allocation:
"This CAPEX was not announced in previous quarter call"
• Mgmt states most of the returns would be invested in business.
• Investment made with intention to correct past ratios which were subdued.
• After this expansion revenue is expected to be double.
Packing business:
• Uflex is running at high utlization level, but there is no point of investing more in these business, as packing business commands less margins, and these less space available.
• While films are getting on higher margins business which is also the focus.
BOPET:
• Dips in the margins in month of November, as post Diwali was the lull period, but Dec and Jan its is back to Oct level, and now indicates stable margins.
• Raw material price decrease due to drastic lower demand in petrochemical.
Expansion:
• Overseas capacity is 1,25,000 MTPA.
• FY 22,23 will have left about minimum CAPEX of around 600 crore.
• There is not stated organised vs unorganised market share, and looking at packaging consumption Uflex is market leader as well.
Debt:
• Ideal situation in case of no growth is to pay off debt or dividends.
• India debt is 750 crore, while India EBIDTA is 750 crores, which is conservative.
• Next year co. expects EBIDTA of 2,000cr, hence new debt too will have ratio of lower than 2 (EBIDTA/Debt)
Huhtamaki:
• Uflex is a integrated players while Huhtmaki is not a integrated players, as they buy packing films, inks, adhesives from the market, which makes Uflex margin better than Huhtamaki.
Acquisition:
• Acquisition usually in packing business have EBIDTA multiple of 12-14x.
• Hence the cos who do not have different use of capital they usually go for acquisition.
• While, the market is itself is small (fragmented market), and there is plenty space for growth.
Geographic result:
• Q3 Poland was less as there was some balancing work left in the plant.
• Russia in this quarter is about 6,500 tones.
Promoter Holding:
• Mgmt focus more on growing the pie, and increase the share and no intent to cash out the money and stop the growth.
• There is no need to making institutional investor happier by taking the buyback.
• Mgmt focus more on business.
Next 2-3 year:
• It is a commodity business. There is cheap money available. Margins currently are lucrative as well. This will lead to expansion from other companies as well. This will sub-due the margins in the next 2-3 year. But this shod
For stock market information do join our Telegram channel:
Deepak Nitrite Ltd conference call was today at 12:00 clock
"Expects to grow at about 25% growth in next couple of years"
Here are the key takeaways Thread
Business Updates:
• Growth is from the segment of specialty chemical and Phenolics.
• Demand and utilization returning to pre-covid level.
• Recovery in domestic economic market (around 31% growth), with export revenue growth by 12.9%
• Segmental result shown in image
Development:
• Land development activity has commenced at the newly acquired site measuring 127 acres at Dahej.
• Balance Sheet of the company remains strong.
• Growth in Phenolics was majorly because of volume growth. Deepak Phenolics at D/E ratio of 0.28 times.
• Speed of filing products has been increased. Filed 5 new DMFs – 3 in US and 2 in EU
• Currently ramping up the facility in VIZAG with strong customer attraction, and will be commercialized as planned in Q3
• VIZAG EBIDTA growth guidance changed to 40%+ YoY
• Growth Driver: Broad based growth in other products and Vizag.
• PLI: Company has filed Mysore for PLI scheme for 1 molecule.
• Technology: Company is about to complete its 2 out of 3 technology, which will enhance efficiency for Solara.